Curated News
By: NewsRamp Editorial Staff
October 20, 2026
NanoViricides' NV-387 Shows Safety in Juvenile Mice, Paving Way for Pediatric Trials
TLDR
- NanoViricides' NV-387 pediatric safety data positions the company to advance a broad-spectrum antiviral into trials for Ebola, Mpox, and measles, gaining a first-mover advantage.
- A 12-day repeated-dose juvenile mouse study tested NV-387 Oral Gummies, finding no toxicity and establishing a NOAEL of 3,690 mg/kg/day without a maximum tolerated dose.
- NanoViricides' NV-387 could soon protect children from deadly viruses like Ebola and measles, offering hope for better global health outcomes.
- NanoViricides' NV-387, a broad-spectrum antiviral, is being tested as tasty oral gummies for kids and has already received FDA orphan drug designations.
Impact - Why it Matters
The positive juvenile toxicity results for NV-387 are a critical step toward expanding this broad-spectrum antiviral into pediatric populations, where safe treatment options for Ebola, Mpox, and measles are urgently needed. If NV-387 proves effective in children, it could provide a much-needed weapon against outbreaks that disproportionately affect vulnerable young patients. For NanoViricides, these findings strengthen the case for partnerships and nondilutive funding, which are essential given the company's going-concern warning. The news matters because it signals progress in developing a platform that could address multiple deadly viruses with a single drug, potentially transforming how we respond to future epidemics.
Summary
NanoViricides, Inc. (NYSE American: NNVC) has announced positive results from a juvenile mouse study evaluating the safety, tolerability, and toxicity of its broad-spectrum antiviral drug NV-387. The 12-day repeated-dose study found that NV-387 Oral Gummies were well tolerated at all tested dose levels, with no mortality, systemic toxicity, or treatment-related adverse effects. The highest tested dose of 3,690 mg/kg/day was established as the No Observed Adverse Effect Level (NOAEL), and no maximum tolerated dose was identified. The company believes these findings could support pediatric enrollment in future clinical trials for Ebola, Mpox, and measles, subject to further clinical development and regulatory requirements.
NV-387 is currently being evaluated in Phase II clinical trials for Ebola and Mpox in the Democratic Republic of Congo. The drug has also received U.S. Food and Drug Administration orphan drug and rare pediatric disease designations for measles. Separately, NanoViricides disclosed that its fiscal 2026 annual report included an auditor statement expressing substantial doubt about its ability to continue as a going concern. The company is pursuing potential nondilutive funding for clinical development while maintaining access to equity-based financing, including an at-the-market share offering facility. To view the full press release, visit https://ibn.fm/5QClt.
NanoViricides, Inc. (www.nanoviricides.com) is a clinical-stage company creating special-purpose nanomaterials for antiviral therapy. Its novel nanoviricide(TM) class of drug candidates and technology are based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc. The company’s lead drug candidate, NV-387, is a broad-spectrum antiviral planned for development as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. Other advanced candidates include NV-HHV-1 for shingles. NanoViricides is also developing drugs against a range of viral diseases, including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The company’s platform technology is based on the TheraCour® nanomedicine technology, which TheraCour licenses from AllExcel, and NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting specific human viral diseases.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides' NV-387 Shows Safety in Juvenile Mice, Paving Way for Pediatric Trials
